Our COVID-19 Response
As a response to the COVID-19 crisis, we are currently developing an antibody test kit for COVID-19. Developing a high quality diagnostic test can take years of research before a prototype is available for evaluation and clinical trials. Cellabs' expertise and proven track record in diagnostic test design and development allows for the timely completion of this project. We are aiming to design, develop and manufacture the first Australian COVID-19 antibody ELISA kit for professional use in laboratories. Following this, a rapid diagnostic test (RDT) for antibody will also be developed for point of care (POC) use.
The Cellabs COVID-19 CELISA
The Cellabs COVID-19 Nucleoprotien (NP) Antibody CELISA is now in its last stages of commercialisation. The kit is designed to detect NP antibodies IgA, IgG and IgM. The kit is packaged as a one-plate kit (Product Code KVN) and a 5-plate kit (Product Code KVN-Bulk) with the option of using a Horseradish Peroxidase (HRP) conjugated monoclonal antibody detector targeting IgA, IgG or IgM. Evaluation studies are currently being conducted for this assay. If you would like to get involved with this assay evaluation, Contact Us.
The Cellabs COVID-19 Spike (S) Antibody CELISA (IgA, IgG and IgM) development is also in the pipeline, approaching its final development stages.
Also in the pipeline is a COVID-19 Neutralising Assay. This assay is currently in its second stage of development expected to be finalised by the middle of June 2021.
If you are interested in these products, please contact us to discuss.